Clinical Trials Browser

Interventional × Irinotecan × 1 year × Clear all

NCT04796012 2026-04-16

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Phase 1/2 Recruiting

Rhabdomyosarcoma

NCT07409272 2026-04-16

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02143219 2026-04-15

PAMELA70

Phase 2 Completed

72 enrolled 7 charts

Gastrointestinal

Pancreatic Metastatic Cancer

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Active not recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT06974110 2026-04-15

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

GastrointestinalGynecologic

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06995872 2026-04-15

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Phase 1 Recruiting

Neuroblastoma

NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Phase 1 Completed

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

NCT00509353 2026-04-14

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Phase 1 Completed

Neuroblastoma

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT06172296 2026-04-14

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT00045201 2026-04-13

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Adult Solid Neoplasm

NCT02567435 2026-04-13

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

325 enrolled 14 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT02595931 2026-04-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

17 enrolled 14 charts

Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

NCT04920032 2026-04-13

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Phase 1 Recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04924192 2026-04-13

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Phase 2 Terminated

Advanced Lung Carcinoma

NCT05379595 2026-04-13

OrigAMI-1

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05440786 2026-04-13

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Phase 2 Active not recruiting

46 enrolled 19 charts

Neoplasm Metastasis, Sarcoma, Ewing

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06459180 2026-04-13

TroFuse-020

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT06662786 2026-04-13

OrigAMI-2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-04-13

OrigAMI-3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Phase 1/2 Recruiting

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT07265674 2026-04-09

Beacon-BTC

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06958328 2026-04-08

LAP100

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07415031 2026-04-08

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT07518147 2026-04-08

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Phase 3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05677490 2026-04-07

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT00213486 2026-04-06

Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT07328425 2026-04-03

ISG-TULIPS

Phase 2 Recruiting

Desmoplastic Small Round Cell Tumor

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT00980460 2026-03-31

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Phase 3 Active not recruiting

236 enrolled 18 charts

Gastrointestinal

PRETEXT I Hepatoblastoma

NCT02366819 2026-03-30

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Phase 4 Suspended

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

Neoplasms

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05838768 2026-03-24

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Phase 1 Active not recruiting

Gastrointestinal

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT05863195 2026-03-23

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Phase 2 Recruiting

Neuroblastoma

NCT05319730 2026-03-20

MK-3475-06B

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03715933 2026-03-18

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Phase 1 Recruiting

Sarcoma, Sarcoma, Ewing

NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

NCT05384821 2026-03-18

MetroWilms

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

NCT05806931 2026-03-18

SCOTI

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1 Recruiting

Neoplasm Metastasis

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

Sarcoma, Ewing